Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-10-17

AUTHORS

F. Nolte, B. Höchsmann, A. Giagounidis, M. Lübbert, U. Platzbecker, D. Haase, A. Lück, N. Gattermann, M. Taupitz, M. Baier, O. Leismann, A. Junkes, C. Schumann, W. K. Hofmann, H. Schrezenmeier

ABSTRACT

The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (± 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (≥ 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations. More... »

PAGES

191-198

Journal

TITLE

Annals of Hematology

ISSUE

2

VOLUME

92

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z

DOI

http://dx.doi.org/10.1007/s00277-012-1594-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017282293

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23073603


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chelation Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Creatinine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deferasirox", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Eruptions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ferritins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Chelating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron Overload", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfusion Reaction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411778.c", 
          "name": [
            "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nolte", 
        "givenName": "F.", 
        "id": "sg:person.0603675126.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603675126.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6582.9", 
          "name": [
            "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "H\u00f6chsmann", 
        "givenName": "B.", 
        "id": "sg:person.01354105066.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354105066.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik II, H\u00e4matologie und Onkologie, St. Johannes Hospital, Duisburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.459950.4", 
          "name": [
            "Medizinische Klinik II, H\u00e4matologie und Onkologie, St. Johannes Hospital, Duisburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giagounidis", 
        "givenName": "A.", 
        "id": "sg:person.01164215515.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr Innere Medizin I, H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Abteilung f\u00fcr Innere Medizin I, H\u00e4matologie und Onkologie, Universit\u00e4tsklinikum Freiburg, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcbbert", 
        "givenName": "M.", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Germany", 
          "id": "http://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Medizinische Klinik und Poliklinik I, Universit\u00e4tsklinikum Carl Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Platzbecker", 
        "givenName": "U.", 
        "id": "sg:person.0670313557.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411984.1", 
          "name": [
            "Abteilung f\u00fcr H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin G\u00f6ttingen, G\u00f6ttingen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haase", 
        "givenName": "D.", 
        "id": "sg:person.0754465332.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Onkologisch-urologische Praxis, Rostock, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Onkologisch-urologische Praxis, Rostock, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcck", 
        "givenName": "A.", 
        "id": "sg:person.01011222414.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011222414.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Abteilung f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gattermann", 
        "givenName": "N.", 
        "id": "sg:person.01273447501.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Radiologie und Klinik f\u00fcr Strahlenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Institut f\u00fcr Radiologie und Klinik f\u00fcr Strahlenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taupitz", 
        "givenName": "M.", 
        "id": "sg:person.01116413157.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116413157.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baier", 
        "givenName": "M.", 
        "id": "sg:person.0637560050.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637560050.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leismann", 
        "givenName": "O.", 
        "id": "sg:person.0770220465.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770220465.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma GmbH, N\u00fcrnberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.467675.1", 
          "name": [
            "Novartis Pharma GmbH, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Junkes", 
        "givenName": "A.", 
        "id": "sg:person.0653772065.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653772065.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411778.c", 
          "name": [
            "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schumann", 
        "givenName": "C.", 
        "id": "sg:person.01037616506.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037616506.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411778.c", 
          "name": [
            "III. Medizinische Klinik, H\u00e4matologie und Onkologie, Universit\u00e4tsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hofmann", 
        "givenName": "W. K.", 
        "id": "sg:person.0710371040.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710371040.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6582.9", 
          "name": [
            "Institut f\u00fcr klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-W\u00fcrttemberg\u2014Hessen und Universit\u00e4t Ulm, Ulm, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schrezenmeier", 
        "givenName": "H.", 
        "id": "sg:person.01236224761.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236224761.06"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00277-012-1481-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187265", 
          "https://doi.org/10.1007/s00277-012-1481-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-010-1091-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003969238", 
          "https://doi.org/10.1007/s00277-010-1091-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280000251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050991082", 
          "https://doi.org/10.1007/s002280000251"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-10-17", 
    "datePublishedReg": "2012-10-17", 
    "description": "The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of >\u20094 units PRBC per month were initially treated with 30\u00a0mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20\u00a0mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6\u00a0mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69\u00a0years who were treated with DFX for a median duration of 354\u00a0days. Mean daily dose of DFX was 19\u00a0mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447\u00a0ng/mL and decreased to 1,685\u00a0ng/mL (reduction by 31\u00a0%) at end of study (p\u2009=\u20090.01). In 7 (13\u00a0%) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8\u00a0mg/g dry tissue weight (\u00b1 8.3\u00a0mg/g dry tissue weight) at study entry to 10,8\u00a0mg/g dry tissue weight (\u00b1 10.4\u00a0mg/g dry tissue weight) at end of study (p\u2009=\u20090.01). Of all patients exposed to the study drug (n\u2009=\u200954), 28 (52\u00a0%) did not complete the 12\u00a0month study period most commonly due to AEs in 28\u00a0% (n\u2009=\u200915) and abnormal laboratory values in 7\u00a0% (n\u2009=\u20094), respectively. The most common adverse events (\u2265\u200910\u00a0% of all patients) with suspected drug relationship were diarrhea (n\u2009=\u200925, 46\u00a0%), nausea (n\u2009=\u200913, 24\u00a0%), upper abdominal pain (n\u2009=\u20098, 15\u00a0%), serum creatinine increase (n\u2009=\u200916, 30\u00a0%) and rash (n\u2009=\u20095, 9\u00a0%). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61\u00a0%). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11\u00a0%). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-012-1594-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "92"
      }
    ], 
    "keywords": [
      "packed red blood cells", 
      "liver iron concentration", 
      "end of study", 
      "serum ferritin levels", 
      "transfusion-dependent iron overload", 
      "myelodysplastic syndrome", 
      "multi-center trial", 
      "iron overload", 
      "study drug", 
      "adverse events", 
      "ferritin levels", 
      "int-1 risk myelodysplastic syndrome", 
      "tissue weight", 
      "liver MRI", 
      "median serum ferritin levels", 
      "units Packed Red Blood Cells", 
      "total body iron content", 
      "safety of deferasirox", 
      "risk MDS patients", 
      "upper abdominal pain", 
      "serum creatinine increase", 
      "common adverse events", 
      "risk myelodysplastic syndromes", 
      "majority of patients", 
      "abnormal laboratory values", 
      "initiation of treatment", 
      "liver iron content", 
      "body iron content", 
      "month study period", 
      "transfusion frequency", 
      "oral deferasirox", 
      "abdominal pain", 
      "creatinine increase", 
      "hematologic improvement", 
      "red blood cells", 
      "median duration", 
      "regular transfusions", 
      "median age", 
      "daily dose", 
      "study entry", 
      "dose adjustment", 
      "MDS patients", 
      "MDS patients", 
      "safety profile", 
      "IWG criteria", 
      "one patient", 
      "laboratory values", 
      "chelation therapy", 
      "unsatisfactory efficacy", 
      "patients", 
      "deferasirox", 
      "dry tissue weight", 
      "single arm", 
      "blood cells", 
      "study period", 
      "MRI", 
      "LIC measurements", 
      "dose", 
      "baseline", 
      "efficacy", 
      "drug relationship", 
      "syndrome", 
      "excess iron", 
      "trials", 
      "days", 
      "drugs", 
      "overload", 
      "safety", 
      "nausea", 
      "transfusion", 
      "rash", 
      "pain", 
      "diarrhea", 
      "anemia", 
      "previous observations", 
      "therapy", 
      "study", 
      "iron concentration", 
      "months", 
      "age", 
      "iron content", 
      "levels", 
      "treatment", 
      "risk", 
      "weight", 
      "sufficient reduction", 
      "duration", 
      "events", 
      "cells", 
      "arm", 
      "majority", 
      "population", 
      "initiation", 
      "years", 
      "interruption", 
      "end", 
      "adjustment", 
      "period", 
      "criteria", 
      "increase", 
      "entry", 
      "reduction", 
      "improvement", 
      "profile", 
      "concentration", 
      "results", 
      "frequency", 
      "data", 
      "relationship", 
      "detection", 
      "intention", 
      "measurements", 
      "content", 
      "tool", 
      "values", 
      "observations", 
      "iron", 
      "method", 
      "et al", 
      "AES", 
      "al"
    ], 
    "name": "Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload", 
    "pagination": "191-198", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017282293"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-012-1594-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23073603"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-012-1594-z", 
      "https://app.dimensions.ai/details/publication/pub.1017282293"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_564.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-012-1594-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-012-1594-z'


 

This table displays all metadata directly associated to this object as RDF triples.

418 TRIPLES      21 PREDICATES      173 URIs      162 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-012-1594-z schema:about N096db8f94b8a4377aec5cf81d50bf15a
2 N0cb1a6773105458ab8e85326a0ab9b9b
3 N160428f0035e4cf382abdf395a6e74e3
4 N20d497ea4eeb47f5868afe4a8c3aa950
5 N2302aa31ac824ba888fd166b605e6ebf
6 N2bf26836e6c54598aa63d0075816191b
7 N38601cb8b22f4d46a614793dee17147f
8 N3deb3972a0e64737b2cec5ef5bc3b4c9
9 N56c045d4040a499682be19822a71da68
10 N6406ba262ee246778a4be8fd352f54d4
11 N7cf2e0ab3378491eb1ff779b570e4b90
12 N871e6dfa7e0d4faa9d8b2e5edeaa12fd
13 N8769e1b633fa4b2e9a1213a037bf7034
14 Na12002d05681411f86bf148faa3b2887
15 Na1edc66015514182af824f11527dfb48
16 Na5ab3a0c6c624c00ac197d936ac33eca
17 Nbbf7132477694229b433bad19ee76c4d
18 Ncb27ddbc407d4d938dff508d73de8880
19 Nce31beafefaf4acaab989f2dcd8fcec8
20 Nd3e492f5af844ed4bce6a4334c3e256f
21 Ndf5af2020f5c4e25ac924e32d3a707fe
22 Ne1a72624a1844999af7713a48393fce5
23 Nf4b8967306374751b094baeb18aab67c
24 Nff65294a3e534e26b0d9d7e46f2468a7
25 Nff9e0ad59a464c8da2f12f82c963bed2
26 anzsrc-for:11
27 anzsrc-for:1103
28 schema:author N71d6d8e6d4844d928dc7417ff08f1d06
29 schema:citation sg:pub.10.1007/s002280000251
30 sg:pub.10.1007/s00277-010-1091-1
31 sg:pub.10.1007/s00277-012-1481-7
32 schema:datePublished 2012-10-17
33 schema:datePublishedReg 2012-10-17
34 schema:description The majority of patients with myelodysplastic syndrome (MDS) present with anemia and will become dependent on regular transfusions of packed red blood cells (PRBC) with the risk of iron overload (IOL). Liver iron content best reflects the total body iron content, and measurement of liver iron concentration (LIC) by MRI is a validated tool for detection, but data in MDS is rather limited. Here we present the results of a multi-center trial evaluating the efficacy and safety of deferasirox (DFX) in low and intermediate-1 risk MDS patients with transfusion-dependent IOL. Three patients with transfusion frequency of > 4 units PRBC per month were initially treated with 30 mg/kg/day while in 46 patients with a lower transfusion burden deferasirox was initiated at 20 mg/kg/day, due to patient related reasons one patient received DFX in a dose of 6 mg/kg/day only. LIC was measured by MRI at baseline and end of study using the method by St. Pierre et al. The intention to treat population consisted of 50 MDS patients (28 male; 22 female) with a median age of 69 years who were treated with DFX for a median duration of 354 days. Mean daily dose of DFX was 19 mg/kg/day. Median serum ferritin level (SF) at baseline was 2,447 ng/mL and decreased to 1,685 ng/mL (reduction by 31 %) at end of study (p = 0.01). In 7 (13 %) patients the initially chosen dose had to be increased due to unsatisfactory efficacy of chelation therapy. For 21 patients, LIC measurement by liver MRI was performed at baseline and for 19 of these patients at the end of study: mean LIC decreased significantly from 16,8 mg/g dry tissue weight (± 8.3 mg/g dry tissue weight) at study entry to 10,8 mg/g dry tissue weight (± 10.4 mg/g dry tissue weight) at end of study (p = 0.01). Of all patients exposed to the study drug (n = 54), 28 (52 %) did not complete the 12 month study period most commonly due to AEs in 28 % (n = 15) and abnormal laboratory values in 7 % (n = 4), respectively. The most common adverse events (≥ 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %). Adverse events making dose adjustments or interruption of study drug necessary occurred in 33 patients (61 %). Hematologic improvement according to IWG criteria (2006) was observed in 6 patients (11 %). Initiation of treatment of IOL with DFX depending on the transfusion burden yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. The safety profile of DFX was comparable to previous observations.
35 schema:genre article
36 schema:isAccessibleForFree false
37 schema:isPartOf N436697c8918d433dbece8dc0519afbd2
38 Nae57b4b81c364d908ac886b79c952091
39 sg:journal.1358129
40 schema:keywords AES
41 IWG criteria
42 LIC measurements
43 MDS patients
44 MRI
45 abdominal pain
46 abnormal laboratory values
47 adjustment
48 adverse events
49 age
50 al
51 anemia
52 arm
53 baseline
54 blood cells
55 body iron content
56 cells
57 chelation therapy
58 common adverse events
59 concentration
60 content
61 creatinine increase
62 criteria
63 daily dose
64 data
65 days
66 deferasirox
67 detection
68 diarrhea
69 dose
70 dose adjustment
71 drug relationship
72 drugs
73 dry tissue weight
74 duration
75 efficacy
76 end
77 end of study
78 entry
79 et al
80 events
81 excess iron
82 ferritin levels
83 frequency
84 hematologic improvement
85 improvement
86 increase
87 initiation
88 initiation of treatment
89 int-1 risk myelodysplastic syndrome
90 intention
91 interruption
92 iron
93 iron concentration
94 iron content
95 iron overload
96 laboratory values
97 levels
98 liver MRI
99 liver iron concentration
100 liver iron content
101 majority
102 majority of patients
103 measurements
104 median age
105 median duration
106 median serum ferritin levels
107 method
108 month study period
109 months
110 multi-center trial
111 myelodysplastic syndrome
112 nausea
113 observations
114 one patient
115 oral deferasirox
116 overload
117 packed red blood cells
118 pain
119 patients
120 period
121 population
122 previous observations
123 profile
124 rash
125 red blood cells
126 reduction
127 regular transfusions
128 relationship
129 results
130 risk
131 risk MDS patients
132 risk myelodysplastic syndromes
133 safety
134 safety of deferasirox
135 safety profile
136 serum creatinine increase
137 serum ferritin levels
138 single arm
139 study
140 study drug
141 study entry
142 study period
143 sufficient reduction
144 syndrome
145 therapy
146 tissue weight
147 tool
148 total body iron content
149 transfusion
150 transfusion frequency
151 transfusion-dependent iron overload
152 treatment
153 trials
154 units Packed Red Blood Cells
155 unsatisfactory efficacy
156 upper abdominal pain
157 values
158 weight
159 years
160 schema:name Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload
161 schema:pagination 191-198
162 schema:productId N36fbd4979a0644da8ae465750bb322ed
163 Na19cd4dcd8404be2b5c71cf3c75af2cd
164 Na30c8e15f2594dd88435eac86eab8dbd
165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017282293
166 https://doi.org/10.1007/s00277-012-1594-z
167 schema:sdDatePublished 2022-10-01T06:37
168 schema:sdLicense https://scigraph.springernature.com/explorer/license/
169 schema:sdPublisher N5dae812939e2410ca9bc6b57936cae5c
170 schema:url https://doi.org/10.1007/s00277-012-1594-z
171 sgo:license sg:explorer/license/
172 sgo:sdDataset articles
173 rdf:type schema:ScholarlyArticle
174 N0108738691f34437908ccab8347ca165 rdf:first sg:person.0637560050.50
175 rdf:rest N699826726a2c48f8bb555f8c78d17baa
176 N0480698cb50245deb6a26d6e5a67dedb rdf:first sg:person.0710371040.30
177 rdf:rest Na0077e2cd6a54cb0b5baae2d7a81dd62
178 N096db8f94b8a4377aec5cf81d50bf15a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Magnetic Resonance Imaging
180 rdf:type schema:DefinedTerm
181 N0cb1a6773105458ab8e85326a0ab9b9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Adult
183 rdf:type schema:DefinedTerm
184 N136fbd3c990244eeb32f1334624d04bd rdf:first sg:person.01037616506.85
185 rdf:rest N0480698cb50245deb6a26d6e5a67dedb
186 N160428f0035e4cf382abdf395a6e74e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Myelodysplastic Syndromes
188 rdf:type schema:DefinedTerm
189 N20d497ea4eeb47f5868afe4a8c3aa950 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Administration, Oral
191 rdf:type schema:DefinedTerm
192 N2302aa31ac824ba888fd166b605e6ebf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Creatinine
194 rdf:type schema:DefinedTerm
195 N2bf26836e6c54598aa63d0075816191b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Gastrointestinal Diseases
197 rdf:type schema:DefinedTerm
198 N358cee729c1d485a9823f1ec037b74dd rdf:first sg:person.01116413157.95
199 rdf:rest N0108738691f34437908ccab8347ca165
200 N36fbd4979a0644da8ae465750bb322ed schema:name dimensions_id
201 schema:value pub.1017282293
202 rdf:type schema:PropertyValue
203 N38601cb8b22f4d46a614793dee17147f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Middle Aged
205 rdf:type schema:DefinedTerm
206 N3deb3972a0e64737b2cec5ef5bc3b4c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Treatment Outcome
208 rdf:type schema:DefinedTerm
209 N436697c8918d433dbece8dc0519afbd2 schema:issueNumber 2
210 rdf:type schema:PublicationIssue
211 N54bf67aecce64f6ba9881c9a7f04a92a rdf:first sg:person.01164215515.10
212 rdf:rest Nb66b5d422d4b421fa7c3f18364cb7b34
213 N56c045d4040a499682be19822a71da68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Deferasirox
215 rdf:type schema:DefinedTerm
216 N5aabbbe74ecb4904a0b9ff905ff7078f rdf:first sg:person.01011222414.69
217 rdf:rest N712af8be1c834f9ea5ca39f9a84d6f46
218 N5dae812939e2410ca9bc6b57936cae5c schema:name Springer Nature - SN SciGraph project
219 rdf:type schema:Organization
220 N6406ba262ee246778a4be8fd352f54d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Female
222 rdf:type schema:DefinedTerm
223 N699826726a2c48f8bb555f8c78d17baa rdf:first sg:person.0770220465.02
224 rdf:rest N7c6f7ef18f5948aea0f41fe7666c27df
225 N712af8be1c834f9ea5ca39f9a84d6f46 rdf:first sg:person.01273447501.34
226 rdf:rest N358cee729c1d485a9823f1ec037b74dd
227 N71d6d8e6d4844d928dc7417ff08f1d06 rdf:first sg:person.0603675126.07
228 rdf:rest N797a4c4f8c9d400d9b6036a335562e3e
229 N797a4c4f8c9d400d9b6036a335562e3e rdf:first sg:person.01354105066.45
230 rdf:rest N54bf67aecce64f6ba9881c9a7f04a92a
231 N7c6f7ef18f5948aea0f41fe7666c27df rdf:first sg:person.0653772065.10
232 rdf:rest N136fbd3c990244eeb32f1334624d04bd
233 N7cf2e0ab3378491eb1ff779b570e4b90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
234 schema:name Humans
235 rdf:type schema:DefinedTerm
236 N8117276f44fc46f0802ac714a90fbb14 rdf:first sg:person.0754465332.53
237 rdf:rest N5aabbbe74ecb4904a0b9ff905ff7078f
238 N871e6dfa7e0d4faa9d8b2e5edeaa12fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
239 schema:name Chelation Therapy
240 rdf:type schema:DefinedTerm
241 N8769e1b633fa4b2e9a1213a037bf7034 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
242 schema:name Iron Overload
243 rdf:type schema:DefinedTerm
244 Na0077e2cd6a54cb0b5baae2d7a81dd62 rdf:first sg:person.01236224761.06
245 rdf:rest rdf:nil
246 Na12002d05681411f86bf148faa3b2887 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
247 schema:name Liver
248 rdf:type schema:DefinedTerm
249 Na19cd4dcd8404be2b5c71cf3c75af2cd schema:name doi
250 schema:value 10.1007/s00277-012-1594-z
251 rdf:type schema:PropertyValue
252 Na1edc66015514182af824f11527dfb48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
253 schema:name Aged
254 rdf:type schema:DefinedTerm
255 Na30c8e15f2594dd88435eac86eab8dbd schema:name pubmed_id
256 schema:value 23073603
257 rdf:type schema:PropertyValue
258 Na5ab3a0c6c624c00ac197d936ac33eca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name Iron Chelating Agents
260 rdf:type schema:DefinedTerm
261 Nae57b4b81c364d908ac886b79c952091 schema:volumeNumber 92
262 rdf:type schema:PublicationVolume
263 Nb66b5d422d4b421fa7c3f18364cb7b34 rdf:first sg:person.01153663723.53
264 rdf:rest Nc4fdfd4aa27f4464942a5cbb8ff4f32a
265 Nbbf7132477694229b433bad19ee76c4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
266 schema:name Ferritins
267 rdf:type schema:DefinedTerm
268 Nc4fdfd4aa27f4464942a5cbb8ff4f32a rdf:first sg:person.0670313557.25
269 rdf:rest N8117276f44fc46f0802ac714a90fbb14
270 Ncb27ddbc407d4d938dff508d73de8880 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
271 schema:name Iron
272 rdf:type schema:DefinedTerm
273 Nce31beafefaf4acaab989f2dcd8fcec8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
274 schema:name Benzoates
275 rdf:type schema:DefinedTerm
276 Nd3e492f5af844ed4bce6a4334c3e256f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
277 schema:name Risk
278 rdf:type schema:DefinedTerm
279 Ndf5af2020f5c4e25ac924e32d3a707fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
280 schema:name Drug Eruptions
281 rdf:type schema:DefinedTerm
282 Ne1a72624a1844999af7713a48393fce5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
283 schema:name Male
284 rdf:type schema:DefinedTerm
285 Nf4b8967306374751b094baeb18aab67c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
286 schema:name Aged, 80 and over
287 rdf:type schema:DefinedTerm
288 Nff65294a3e534e26b0d9d7e46f2468a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
289 schema:name Triazoles
290 rdf:type schema:DefinedTerm
291 Nff9e0ad59a464c8da2f12f82c963bed2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
292 schema:name Transfusion Reaction
293 rdf:type schema:DefinedTerm
294 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
295 schema:name Medical and Health Sciences
296 rdf:type schema:DefinedTerm
297 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
298 schema:name Clinical Sciences
299 rdf:type schema:DefinedTerm
300 sg:journal.1358129 schema:issn 0939-5555
301 1432-0584
302 schema:name Annals of Hematology
303 schema:publisher Springer Nature
304 rdf:type schema:Periodical
305 sg:person.01011222414.69 schema:affiliation grid-institutes:None
306 schema:familyName Lück
307 schema:givenName A.
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011222414.69
309 rdf:type schema:Person
310 sg:person.01037616506.85 schema:affiliation grid-institutes:grid.411778.c
311 schema:familyName Schumann
312 schema:givenName C.
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037616506.85
314 rdf:type schema:Person
315 sg:person.01116413157.95 schema:affiliation grid-institutes:grid.6363.0
316 schema:familyName Taupitz
317 schema:givenName M.
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116413157.95
319 rdf:type schema:Person
320 sg:person.01153663723.53 schema:affiliation grid-institutes:grid.7708.8
321 schema:familyName Lübbert
322 schema:givenName M.
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
324 rdf:type schema:Person
325 sg:person.01164215515.10 schema:affiliation grid-institutes:grid.459950.4
326 schema:familyName Giagounidis
327 schema:givenName A.
328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10
329 rdf:type schema:Person
330 sg:person.01236224761.06 schema:affiliation grid-institutes:grid.6582.9
331 schema:familyName Schrezenmeier
332 schema:givenName H.
333 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236224761.06
334 rdf:type schema:Person
335 sg:person.01273447501.34 schema:affiliation grid-institutes:grid.411327.2
336 schema:familyName Gattermann
337 schema:givenName N.
338 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34
339 rdf:type schema:Person
340 sg:person.01354105066.45 schema:affiliation grid-institutes:grid.6582.9
341 schema:familyName Höchsmann
342 schema:givenName B.
343 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354105066.45
344 rdf:type schema:Person
345 sg:person.0603675126.07 schema:affiliation grid-institutes:grid.411778.c
346 schema:familyName Nolte
347 schema:givenName F.
348 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603675126.07
349 rdf:type schema:Person
350 sg:person.0637560050.50 schema:affiliation grid-institutes:grid.467675.1
351 schema:familyName Baier
352 schema:givenName M.
353 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637560050.50
354 rdf:type schema:Person
355 sg:person.0653772065.10 schema:affiliation grid-institutes:grid.467675.1
356 schema:familyName Junkes
357 schema:givenName A.
358 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653772065.10
359 rdf:type schema:Person
360 sg:person.0670313557.25 schema:affiliation grid-institutes:grid.412282.f
361 schema:familyName Platzbecker
362 schema:givenName U.
363 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25
364 rdf:type schema:Person
365 sg:person.0710371040.30 schema:affiliation grid-institutes:grid.411778.c
366 schema:familyName Hofmann
367 schema:givenName W. K.
368 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710371040.30
369 rdf:type schema:Person
370 sg:person.0754465332.53 schema:affiliation grid-institutes:grid.411984.1
371 schema:familyName Haase
372 schema:givenName D.
373 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53
374 rdf:type schema:Person
375 sg:person.0770220465.02 schema:affiliation grid-institutes:grid.467675.1
376 schema:familyName Leismann
377 schema:givenName O.
378 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770220465.02
379 rdf:type schema:Person
380 sg:pub.10.1007/s002280000251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050991082
381 https://doi.org/10.1007/s002280000251
382 rdf:type schema:CreativeWork
383 sg:pub.10.1007/s00277-010-1091-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003969238
384 https://doi.org/10.1007/s00277-010-1091-1
385 rdf:type schema:CreativeWork
386 sg:pub.10.1007/s00277-012-1481-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187265
387 https://doi.org/10.1007/s00277-012-1481-7
388 rdf:type schema:CreativeWork
389 grid-institutes:None schema:alternateName Onkologisch-urologische Praxis, Rostock, Germany
390 schema:name Onkologisch-urologische Praxis, Rostock, Germany
391 rdf:type schema:Organization
392 grid-institutes:grid.411327.2 schema:alternateName Abteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
393 schema:name Abteilung für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
394 rdf:type schema:Organization
395 grid-institutes:grid.411778.c schema:alternateName III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
396 schema:name III. Medizinische Klinik, Hämatologie und Onkologie, Universitätsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany
397 rdf:type schema:Organization
398 grid-institutes:grid.411984.1 schema:alternateName Abteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany
399 schema:name Abteilung für Hämatologie und Onkologie, Universitätsmedizin Göttingen, Göttingen, Germany
400 rdf:type schema:Organization
401 grid-institutes:grid.412282.f schema:alternateName Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
402 schema:name Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
403 rdf:type schema:Organization
404 grid-institutes:grid.459950.4 schema:alternateName Medizinische Klinik II, Hämatologie und Onkologie, St. Johannes Hospital, Duisburg, Germany
405 schema:name Medizinische Klinik II, Hämatologie und Onkologie, St. Johannes Hospital, Duisburg, Germany
406 rdf:type schema:Organization
407 grid-institutes:grid.467675.1 schema:alternateName Novartis Pharma GmbH, Nürnberg, Germany
408 schema:name Novartis Pharma GmbH, Nürnberg, Germany
409 rdf:type schema:Organization
410 grid-institutes:grid.6363.0 schema:alternateName Institut für Radiologie und Klinik für Strahlenheilkunde, Charité Universitätsmedizin Berlin, Berlin, Germany
411 schema:name Institut für Radiologie und Klinik für Strahlenheilkunde, Charité Universitätsmedizin Berlin, Berlin, Germany
412 rdf:type schema:Organization
413 grid-institutes:grid.6582.9 schema:alternateName Institut für klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-Württemberg—Hessen und Universität Ulm, Ulm, Germany
414 schema:name Institut für klinische Transfusionsmedizin und Immungenetik Ulm, DRK Blutspendedienst Baden-Württemberg—Hessen und Universität Ulm, Ulm, Germany
415 rdf:type schema:Organization
416 grid-institutes:grid.7708.8 schema:alternateName Abteilung für Innere Medizin I, Hämatologie und Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
417 schema:name Abteilung für Innere Medizin I, Hämatologie und Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
418 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...